The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Shchulkin A.V.

Ryazan State Medical University

Chernykh I.V.

Ryazan State Medical University

Abalenikhina Y.V.

Ryazan State Medical University

Gatsanoga M.V.

Ryazan State Medical University

Kochetkova D.L.

Ryazan State Medical University

Kruzhalov N.A.

Ryazan State Medical University

Krestinina E.V.

Ryazan State Medical University

Yakusheva E.N.

Ryazan State Medical University

The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents

Authors:

Shchulkin A.V., Chernykh I.V., Abalenikhina Y.V., Gatsanoga M.V., Kochetkova D.L., Kruzhalov N.A., Krestinina E.V., Yakusheva E.N.

More about the authors

Read: 336 times


To cite this article:

Shchulkin AV, Chernykh IV, Abalenikhina YV, et al. The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;125(2):123‑129. (In Russ.)
https://doi.org/10.17116/jnevro2026126021123

Recommended articles:
Personal characteristics of patients with cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56
Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55

References:

  1. Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era. Nat Rev Neurol. 2022;18(4):193-202.  https://doi.org/10.1038/s41582-021-00605-6
  2. Sheth SA. Mechanical Thrombectomy for Acute Ischemic Stroke. Continuum. 2023;29:443-461. https://doi.org/10.1212/CON.0000000000001243
  3. Haupt M, Gerner ST, Bähr M, Doeppner TR. Neuroprotective Strategies for Ischemic Stroke — Future Perspectives. Inr J Mol Sci. 2023;24:4334. https://doi.org/10.3390/ijms24054334
  4. Lyden P, Buchan A, Boltze J, Fisher M. Top priorities for cerebroprotective studies-a paradigm shift: report from STAIR XI. Stroke. 2021;52:3063-3071. https://doi.org/10.1161/STROKEAHA.121.034947
  5. Savitz SI, Baron JC, Fisher M. Stroke Treatment Academic Industry Roundtable X: brain cytoprotection therapies in the reperfusion era. Stroke. 2019;50:1026-1031. https://doi.org/10.1161/STROKEAHA.118.023927
  6. Voronina TA, Litvinova SA, Gladysheva NA, Shulyndin AV. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22-33. (In Russ.). https://doi.org/10.17116/jnevro202512505122
  7. Shchulkin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(2):35-39. (In Russ.).
  8. Shchulkin AV, Chernykh IV, Abalenikhina YuV, et al. The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):107-112. (In Russ.). https://doi.org/10.17116/jnevro2025125021107
  9. Gomazkov OA. Cortexin. Molecular mechanisms and targets of neuroprotective activity. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(8):99-104. (In Russ.). https://doi.org/10.17116/jnevro20151158199-104
  10. Vostrikov VV, Shishlyanikov GZ, Zelentsov KE, et al. Tserebrolizin v prakticheskoi meditsine. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii. 2009;7(4):21-75. (In Russ.).
  11. Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? Pharm Res. 2019;37(1):12.  https://doi.org/10.1007/s11095-019-2745-x
  12. Gromova OA, Torshin IIu, Gogoleva IV, et al. Pharmacokinetic and pharmacodynamic synergism between neuropeptides and lithium in the neurotrophic and neuroprotective action of cerebrolysin. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(3):65-72. (In Russ.). https://doi.org/10.17116/jnevro20151153165-72
  13. Zarubina IV, Buznik GV, Shabanov PD. Neiroprotektornye effekty korteksina i ishemicheskoe prekonditsionirovanie. Pediatr. 2015;6(3):56-61. (In Russ.).
  14. Koizumi J, Yoshida Y, Nakazawa T. Experimental studies of ischemic brain edema. I. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke. 1986;8:1-8.  https://doi.org/10.3995/jstroke.8.1
  15. Shchulkin AV, Yakusheva EN, Chernykh IV. The distribution of mexidol in the rat’s brain and its subcellular fractions. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(8):70-73. (In Russ.).
  16. Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
  17. Lin L, Wang X, Yu Z. Ischemia-reperfusion Injury in the Brain: Mechanisms and Potential Therapeutic Strategies. Biochem Pharmacol (Los Angel). 2016;5(4):213.  https://doi.org/10.4172/2167-0501.1000213
  18. Du J, Gebicki JM. Proteins are major initial cell targets of hydroxyl free radicals. Int J Biochem Cell Biol. 2004;36(11):2334-2343. https://doi.org/10.1016/j.biocel.2004.05.012
  19. Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. https://doi.org/10.1002/med.21960
  20. Velly L, Boumaza D, Simeone P. Cerebral Ischemia: Pathophysiology, Diagnosis, and Management. In: Ichai C, Quintard H, Orban JC. (eds). Metabolic Disorders and Critically Ill Patients. Springer, Cham. 2018. https://doi.org/10.1007/978-3-319-64010-5_13
  21. Kalinin RE, Suchkov IA, Klimentova EA, et al. Biomarkers of Apoptosis and Cell Proliferation in Diagnosing the Progression of Atherosclerosis in Different Vascular Pools. I.P. Pavlov Russian Medical Biological Herald. 2022;30(2):243-252. (In Russ.). https://doi.org/10.17816/PAVLOVJ88938
  22. Gong C, Qin Z, Betz AL, et al. Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice. Brain Res. 1998;801(12):1-8.  https://doi.org/10.1016/s0006-8993(98)00489-2
  23. Korotaeva NV, Ippolitova LI, Ivantsova EN, Pershina ES. Brain-Derived Neurotrophic Factor as a Potential Biomarker of Neurological Disorders in Premature Infants. Science of the Young (Eruditio Juvenium). 2023;11(4):607-614. (In Russ.). https://doi.org/10.23888/HMJ2023114607-614

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.